GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » Debt-to-Asset

ANL (Adlai Nortye) Debt-to-Asset : 0.37 (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Adlai Nortye Debt-to-Asset?

Adlai Nortye's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $39.53 Mil. Adlai Nortye's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.00 Mil. Adlai Nortye's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was $107.68 Mil. Adlai Nortye's debt to asset for the quarter that ended in Jun. 2024 was 0.37.

Adlai Nortye Debt-to-Asset Historical Data

The historical data trend for Adlai Nortye's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adlai Nortye Debt-to-Asset Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-Asset
0.10 0.09 0.24

Adlai Nortye Quarterly Data
Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Jun24
Debt-to-Asset Get a 7-Day Free Trial 0.09 0.18 0.32 0.24 0.37

Competitive Comparison of Adlai Nortye's Debt-to-Asset

For the Biotechnology subindustry, Adlai Nortye's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adlai Nortye's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adlai Nortye's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Adlai Nortye's Debt-to-Asset falls into.


Adlai Nortye Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Adlai Nortye's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(31.079 + 0.469) / 130.189
=0.24

Adlai Nortye's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(39.528 + 0) / 107.682
=0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adlai Nortye  (NAS:ANL) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Adlai Nortye Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Adlai Nortye's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Adlai Nortye Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » Debt-to-Asset
Comparable Companies
ADVM IGMS NTRB ABOS CUE VERU INO ZIVO INZY ACET VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
685 US Highway 1, New Jersey Biotechnology Development Center, 2nd floor, North Brunswick, NJ, USA, 08902
Website
https://www.adlainortye.com
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.